fda compounding glp 1 Novo asks to prevent compounders from making GLP-1 knockoffs The FDA's GLP-1 Compounding Crackdown

Graves' disease is one among many other diseases of the thyroid, but only with certain criteria because it is an autoimmune disease, having origin in the disarray of the immune system

Cellular Repair : This antioxidant is essential for repairing damaged cells and maintaining overall cellular health

It is an inherent consequence of how the medication works

Dysesthesia: A New Signal for Retatrutide The TRIUMPH-4 Phase 3 trial revealed an unexpected finding: dysesthesia (abnormal touch sensations where normal sensations feel unusual or painful) in 20.9% of participants on 12 mg and 8.8% on 9 mg, compared to 0.7% on placebo (BioSpace, Dec 2025)